Innovate With Regulators To Leverage DHT Data As Patient-Centric Primary Endpoints

This presentation explains how the FDA endorsed digital outcome measures of physical activity collected from ActiGraph technology as the primary endpoint in a pivotal cardiopulmonary trial, marking an important milestone for the industry. 

Watch as Chief Executive Officer and Chief Regulatory of Safety and Quality Officer at Bellerophon Therapeutics Peter Fernandes discusses several case studies and strategies for using digital health technology to measure physical activity as the primary endpoint in clinical trials.